Aortic stenosis resident survival guide: Difference between revisions
No edit summary |
No edit summary |
||
Line 26: | Line 26: | ||
==Overview== | ==Overview== | ||
[[Aortic stenosis]] is the progressive narrowing of the diameter of the [[aortic valve]] (normal valve area is 3 - 4 cm²). The symptoms are caused by a decrease in the [[stroke volume]] which reduces blood flow to peripheral tissues. The most common etiology of arotic stenosis is [[calcific aortic valve disease]]. The management of [[aortic stenosis]] depends on whether the patient is symptomatic or asymptomatic | [[Aortic stenosis]] is the progressive narrowing of the diameter of the [[aortic valve]] (normal valve area is 3 - 4 cm²). The symptoms are caused by a decrease in the [[stroke volume]] which reduces blood flow to peripheral tissues. The most common etiology of arotic stenosis is [[calcific aortic valve disease]]. The management of [[aortic stenosis]] depends on whether the patient is symptomatic or asymptomatic, the area of the valve, and the hemodynamic response to exercise. | ||
==Causes== | ==Causes== |
Revision as of 00:47, 8 May 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Aortic Stenosis Resident Survival Guide Microchapters |
---|
Overview |
Causes |
FIRE |
Diagnosis |
Treatment |
Do's |
Don'ts |
Overview
Aortic stenosis is the progressive narrowing of the diameter of the aortic valve (normal valve area is 3 - 4 cm²). The symptoms are caused by a decrease in the stroke volume which reduces blood flow to peripheral tissues. The most common etiology of arotic stenosis is calcific aortic valve disease. The management of aortic stenosis depends on whether the patient is symptomatic or asymptomatic, the area of the valve, and the hemodynamic response to exercise.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Click here for the complete list of causes.
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.[1]
Boxes in the red signify that an urgent management is needed.
Abbreviations: AVR: Aortic valve replacement; CK-MB: Creatine kinase myocardial type; ECG: Electrocardiogram; NSTEMI: Non ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; TTE: Transthoracic echocardiography
Identify cardinal findings that increase the pretest probability of aortic stenosis ❑ Systolic ejection murmur
| |||||||||||||||||||||||||||||||||||||||||||||
Does the patient have any of the following findings of decompensated aortic stenosis that require urgent management? ❑ Tachycardia ❑ Hypotension ❑ Severe dyspnea ❑ Loss of consciousness ❑ Chest pain | |||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||
What is the complication of aortic stenosis that is causing decompensation? | Proceed to the complete diagnostic approach below | ||||||||||||||||||||||||||||||||||||||||||||
❑ Suspect in case of:
| ❑ Suspect in case of palpitations ❑ Order an ECG immediately looking for | ❑ Suspect in case of loss of consciousness of:
| |||||||||||||||||||||||||||||||||||||||||||
❑ Treat the complications of aortic stenosis that lead to decompensation ❑ Order a TTE to evaluate the severity of the aortic stenosis ❑ Do not give nitrates (could cause severe hypotension) ❑ Monitor vital signs continuously | |||||||||||||||||||||||||||||||||||||||||||||
Does the patient improve with medical therapy? | |||||||||||||||||||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||||||||||||||||||
❑ Proceed with urgent AVR | |||||||||||||||||||||||||||||||||||||||||||||
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[1]
Abbreviations: AF: Atrial fibrillation; AVR: Aortic valve replacement; CXR: Chest X-ray; ECG: Electrocardiogram; LBBB: Left bundle branch block; LVH: Left ventricle hypertrophy; TAVR: Transcatheter aortic valve replacement; TTE: Transthoracic echocardiography; VHD: Valvular heart disease
Characterize the symptoms: ❑ Asymptomatic ❑ Dyspnea on exertion ❑ Dizziness on exertion ❑ Syncope ❑ Chest pain ❑ Palpitations | |||||||||||||||||||||||||||||||||||||
Examine the patient: Vitals
❑ Respiratory rate
❑ Pulses
Click on the video below to listen to an aortic stenosis murmur.
{{#ev:youtube|MJg257pyt4I|200}}
| |||||||||||||||||||||||||||||||||||||
Order tests: ❑ TTE (most important evaluation test) (Class I; Level of Evidence: B)
❑ ECG (shows non-specific findings):
❑ Chest X-ray:
| |||||||||||||||||||||||||||||||||||||
Classify aortic stenosis based on the following findings on TTE: ❑ Valve area ❑ Transvalvular pressure gradient | |||||||||||||||||||||||||||||||||||||
No stenosis ❑ Valve area 2.5-3.5 cm² ❑ No pressure gradient across the valve | Mild stenosis ❑ Valve area 1.5-2.5 cm² ❑ Pressure gradient ≤ 25 mmHg | Moderate stenosis ❑ Valve area 1.0-1.5 cm² ❑ Pressure gradient 25-40 mmHg | Severe stenosis ❑ Valve area ≤ 1.0 cm² ❑ Pressure gradient ≥ 40 mmHg | ||||||||||||||||||||||||||||||||||
Treatment
General Approach
Shown below is an algorithm for the treatment of aortic stenosis according to the stage of the disease based on the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease [1]
Abbreviations: AVR: Aortic valve replacement; LVEF: Left ventricular ejection fraction; TTE: Transthoracic echocardiography
Classify aortic stenosis based on the following findings on TTE:
| |||||||||||||||||||||||||||||||||||||||||||||||||
No stenosis (Stage A) ❑ Valve area 2.5-3.5 cm² ❑ No pressure gradient | Mild to moderate stenosis (Stage B) Mild ❑ Valve area 1.5-2.5 cm² ❑ Pressure gradient ≤ 25 mmHg Moderate ❑ Valve area 1.0-1.5 cm² ❑ Pressure gradient 25-40 mmHg | Severe stenosis ❑ Valve area ≤ 1.0 cm² | |||||||||||||||||||||||||||||||||||||||||||||||
Asymptomatic patients ❑ Control hypertension (Class I; Level of Evidence: B) ❑ Perform a periodic echocardiogram (Class I; Level of Evidence:B)
| Asymptomatic (Stage C) ❑ Pressure gradient ≥ 40 mmHg | Symptomatic (Stage D) | |||||||||||||||||||||||||||||||||||||||||||||||
❑ Control hypertension (Class I; Level of Evidence: B) | Normal LVEF (Stage C1) | LVEF < 50% (Stage C2) | High pressure gradient (≥ 40 mmHg) (Stage D1) | ||||||||||||||||||||||||||||||||||||||||||||||
Perform a periodic echocardiogram every 6 - 12 months (Class I; Level of Evidence: B) | ❑ Schedule for AVR (Class I; Level of Evidence: A) | ||||||||||||||||||||||||||||||||||||||||||||||||
If aortic velocity ≥ 5 m/s or there is a decrease in exercise tolerance: ❑ Schedule for AVR (Class IIa; Level of Evidence: B) | |||||||||||||||||||||||||||||||||||||||||||||||||
Choice of Intervention
Shown below is an algorithm summarizing the choice of aortic valve replacement among patients with aortic stenosis based on the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease [1]
Abbreviations: AVR: Aortic valve replacement; TAVR Tansthoracic aortic valve replacement
What is the surgical and interventional risk of the patient? (The risk score is shown below) | |||||||||||||||||||||||||||||||||
High risk | Low to moderate risk | ||||||||||||||||||||||||||||||||
❑ A multidisciplinary group should decide intervention (surgical AVR or TAVR) (Class I; Level of Evidence: C) ❑ Consider TAVR (Class IIa; Level of Evidence: B)[1] [2] | ❑ Schedule for surgical AVR (Class I; Level of Evidence: A) | ||||||||||||||||||||||||||||||||
Evaluation of Surgical and Interventional Cardiac Risk
Shown below is a table to assess the surgical and interventional risk which combines the STS risk estimate, frailty, major organ system dysfunction and procedure-specific impediments.[1]
Society of Thoracic Surgeons Predicted Risk of Mortality Score [3] |
Frailty* | Major organ system compromised without postoperative improvement | Specific procedural impediment ** | |
---|---|---|---|---|
Low risk | <4% AND |
None AND |
None AND |
None |
Intermediate risk | 4% to 8% OR |
1 index OR |
1 organ system OR |
Possible |
High risk | >8% OR |
≥2 indices (moderate to severe) OR |
No more than 2 organ systems OR |
Possible |
Prohibitive risk | >50% of predicted risk of death or major morbidity at 1 year OR |
>50% of predicted risk of death or major morbidity at 1 year OR |
≥3 organ systems | Severe |
*Seven frailty indices: Katz Activites of Daily Living (self-sufficient in feeding, bathing, dressing, transferring, toileting and urinary continence) and self-sufficient in deambulation (no walking aid or assist required or 5-meter walk in <6 s).
**Examples of specific procedural impediment: tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall or radiation damage.
Type of Valve and Discharge Anticoagulation Therapy
Abbreviations: AVR: Aortic valve replacement; INR: International normalized ratio; TAVR Tansthoracic aortic valve replacement
Determine: ❑ Age ❑ Contraindications for anticoagulation
| |||||||||||||||||||||||||||||||||
❑ Patients ≤ 60 years old (Class IIa; Level of Evidence: B), AND ❑ No contraindication for anticoagulation | ❑ Patients 60 - 70 years old ❑ No contraindication for anticoagulation | ❑ Patients ≥ 70 years old (Class IIa; Level of Evidence: B), OR ❑ Patients with contraindications for anticoagulation therapy (Class I; Level of Evidence: C) | |||||||||||||||||||||||||||||||
Mechanical Prosthesis Avoid the use of direct thrombin inhibitors or anti-Xa agents in patients with mechanical prosthesis (Class III; Level of Evidence: B) | Either a bioprosthesic or mechanical valve is reasonable (Class IIa; Level of Evidence: B). | Bioprosthesis | |||||||||||||||||||||||||||||||
Patient with risk factors† | Patient without risk factors† | Surgical AVR | |||||||||||||||||||||||||||||||
Do's
- Administer ACE inhibitors to control hypertension among patients with asymptomatic aortic stenosis.[4]
- Perform a transthoracic echocardiography (TTE) after aortic valve replacement fto evaluate the valve hemodynamics (Class I; Level of Evidence: B).[1]
- Perform a TTE when clinical symptoms or signs suggest prosthetic valve dysfunction (Class I; Level of Evidence: C).[1]
- Consider exercise testing in asymptomatic patients with aortic stenosis to elicit exercise-induced symptoms and abnormal blood pressure responses (Class IIb; Level of Evidence: B).[1]
- Consider dobutamine stress echocardiography to evaluate patients with low-flow/low-gradient AS and LV dysfunction (Stage D3) (Class IIa; Level of Evidence: B).[1]
- Consider aortic balloon valvotomy as a bridge to surgery in hemodynamically unstable adult patients with aortic stenosis among whom aortic valve replacement cannot be performed because of a high surgical risk or due to the presence of serious comorbid conditions.(Class IIb; Level of Evidence: C).[1]
Don'ts
- Do not perform a stress test in a symptomatic patient with stage D aortic stenosis (Class III; Level of Evidence: B).[1]
- Do not administer statins to prevent hemodynamic progression in patients with mild to moderate calcific aortic valve disease (Class III; Level of Evidence: A).[1]
- Do not perform a transcatheter aortic valve implantation (TAVR) among patients in whom existing comorbidities would preclude the expected benefit from the correction of aortic stenosis (Class III; Level of Evidence: B).[1]
- Do not administer vasodilators to patients with severe aortic stenosis because vasodilators may cause severe hypotension which can precipitate or exacerbate the symptoms of aortic stenosis.[1]
- Do not administer endocarditis prophylaxis among patients with aortic stenosis.[5]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 Nishimura, R. A.; Otto, C. M.; Bonow, R. O.; Carabello, B. A.; Erwin, J. P.; Guyton, R. A.; O'Gara, P. T.; Ruiz, C. E.; Skubas, N. J.; Sorajja, P.; Sundt, T. M.; Thomas, J. D. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000031. ISSN 0009-7322.
- ↑ Smith, Craig R.; Leon, Martin B.; Mack, Michael J.; Miller, D. Craig; Moses, Jeffrey W.; Svensson, Lars G.; Tuzcu, E. Murat; Webb, John G.; Fontana, Gregory P.; Makkar, Raj R.; Williams, Mathew; Dewey, Todd; Kapadia, Samir; Babaliaros, Vasilis; Thourani, Vinod H.; Corso, Paul; Pichard, Augusto D.; Bavaria, Joseph E.; Herrmann, Howard C.; Akin, Jodi J.; Anderson, William N.; Wang, Duolao; Pocock, Stuart J. (2011). "Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients". New England Journal of Medicine. 364 (23): 2187–2198. doi:10.1056/NEJMoa1103510. ISSN 0028-4793.
- ↑ "Online STS Risk Calculator". Retrieved 7 March 2014.
- ↑ Chambers, J. (2005). "The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors". Heart. 92 (3): 420–423. doi:10.1136/hrt.2005.074112. ISSN 1355-6037.
- ↑ Bonow, RO.; Carabello, BA.; Chatterjee, K.; de Leon, AC.; Faxon, DP.; Freed, MD.; Gaasch, WH.; Lytle, BW.; Nishimura, RA. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter
|month=
ignored (help)